The board of directors of CARsgen Therapeutics Holdings Limited announced that Dr. Huabing Li has been
appointed as an independent non-executive Director of the Company, the chairman of the remuneration committee, a member of the nomination and corporate governance committee and a member of the audit committee of the Company with effect from March 9, 2023. The biographical details of Dr. Li are set out below:
Dr. Li, aged 42, has rich working experiences in the field of biology, and has worked in Shanghai Jiaotong University School of Medicine Shanghai Institute of Immunology as a Researcher with main responsibilities of the research on epigenetic immunology from December 2017. Prior to this, he served as postdoctoral researcher in Yale University from September 2012 and was a postdoctoral research fellow in Rutgers, the State University of New Jersey from June 2011 to August 2012. Dr. Li earned his Bachelor's degree in Science in Biological Science from College of Life Sciences, Nankai University in June 2002. He obtained Master's degree in Science in Genetics from Nankai University in July 2005 and Ph.D. in Biochemistry and Molecular Biology from Rutgers, The State University of New Jersey in May 2011.